Biotech company closes heavily oversubscribed financing round
More than 70 investors participated in biotech company Synklino's financing round with proceeds going to the drug development for organ transplant patients infected with the herpesvirus cytomegalovirus (CMV).
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Finding the necessary capital to continue operations has been smooth sailing for biotech company Synklino, which reported on Monday that a financing round has concluded, bringing in DKK 106m (USD 16.2m).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Stockholm wants to become leading life science region
For subscribers
